CRP and myocardial infarction: In accordance, the CANTOS study (Canakinumab Anti-Inflammatory Thrombosis Outcome Study), which included approximately 10,000 stable post-myocardial infarction patients with high-sensitivity C-reactive protein, demonstrated the benefit of inhibiting the pro-inflammatory effector molecule interleukin-1β (IL-1β) using the antibody canakinumab.